After centuries of cancer devastating almost half the population, the last decades have brought unprecedented insights into the causation and treatment of this disease.
Some cancers now have effective treatments, but some of the most devastating are mostly untreatable, such as pancreatic, ovarian and brain cancer. A feature of these cancers is their link to our diet and our bodies metabolism. For instance, about 40% of endometrial cancer is attributed to obesity.
The goal of the ACRF Centenary Cancer Research Centre is to understand the link between diet, metabolism and tumour initiation and development at a molecular level, and to design new therapies using this knowledge.
Centenary brings basic research excellence to clinical utility, specializing in its three core competencies of cancer, chronic inflammation and cardiovascular diseases. It has exceptional skills in the burgeoning area of metabolism and cancer and this will continue to be the scientific focus of this new enterprise.
In partnership with the Australian Cancer Research Foundation and Sydney Catalyst, the new ACRF-Centenary Cancer Research Centre expands the capabilities of Centenary’s cancer research stream. The Centre has four core strategic aims: i) making key discoveries about disease mechanisms; ii) their effective translation into the clinic; iii) catalyzing medical research by collaborations and iv) local and international recognition.
The Centre is located within the University of Sydney’s Charles Perkins Centre and will be the first dedicated cancer biology research centre in the Royal Prince Alfred Hospital and the University of Sydney Precinct – a health precinct which is technically excellent, clinically innovative and directly connected to patients.
A core and unique focus of the Centre is to understand the link between our diet, our bodies metabolism and cancer. With new state-of-the-art equipment and some of the best intellectual expertise in the country, this well-positions Centenary and its collaborators and stakeholders to make significant advances in this research area.
Professor Philip Hogg, Head of Program
Sydney Catalyst Chair in Translational Cancer Research
Prof Philip Hogg graduated with a PhD in biochemistry from the University of Queensland in 1987. Following post-doctoral training in the USA and Sweden he returned to UNSW as a NHMRC RD Wright Fellow. He is now a NHMRC Senior Principle Research Fellow and was the inaugural director of the Lowy Cancer Research Centre at UNSW. He has won several national and international awards for his research, which focuses on a fundamental chemical modification of proteins he discovered. This research has led to a potential new cancer diagnostic and a therapeutic that are in clinical testing.
>> View Publications Online